tbuckley/cabot-search huggingface dataset:
Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation.
Authors: Christian Thiede, Sina Koch, Eva Creutzig, Christine Steudel, Thomas Illmer, Markus Schaich, Gerhard Ehninger
Journal: Blood (2005)
Cost Effectiviness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.
Authors: Matthieu Mahévas, Mikael Ebbo, Sylvain Audia, Bernard Bonnotte, Nicolas Schleinitz, Corinne Haioun, Medhi Khellaf, Bertrand Godeau, Marc Michel IV
Journal: Blood (2012)
Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
Authors: Jeff P. Sharman, Leonard Klein, Michael Boxer, Kathryn S. Kolibaba, Michael J. Hawkins, Julie A Di Paolo, Jing Hu, Anita Reddy, Feng Jin, Flordeliza Melchor-Khan, Christopher A. Yasenchak
Journal: Blood (2013)
The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.
Authors: Michele Baccarani, Bengt Simonsson, Doris Lindörfer, Gianantonio Rosti, Antonio M Almeida, Andrija Bogdanovic, Richard E. Clark, Adriana Colita, Paul A. Costeas, Laimonas Griskevicius, Joelle Guilhot, Andrzej Hellmann, Karel Indrak, Edward Laane, Boris Labar, Tamas Masszi, Sandra Lejniece, Jiri Mayer, Gert Ossenkoppele, Panayiotis Panayiotidis, Kimmo Porkka, Susanne Saussele, Andreas Hochhaus, Juan Luis Steegmann, Josef Thaler, Anna Turkina, Gregor Verhoef, Andrey Zaritskey, Irena Preloznik Zupan, Francesca Rancati, Lara Montrucchio, Rüdiger Hehlmann, Joerg Hasford
Journal: Blood (2009)
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
Authors: Chiara Cerrato, Francesca Gay, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Massimo Offidani, Tommasina Guglielmelli, Marco Salvini, Francesca Patriarca, Elena Ponticelli, Gianpietro Semenzato, Francesco Di Raimondo, Roberto Mina, Nicola Cascavilla, Dina Ben Yehuda, Daniela Oddolo, Paolo Corradini, Lucio Catalano, Paolo Di Bartolomeo, Roman Hájek, Andrew Spencer, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2015)
The Anti-CD 20 Mab R603 Induces PTEN and RKIP Expression in B-NHL Cells: Role in Inhibition of Constitutively Activated Akt and NF-ΚB Survival Anti-Apoptotic Pathways.
Authors: Loredana Militello, Stavroula Baritaki, Eriko Suzuki, Mario I. Vega, Margarita Salcedo, Benjamin Bonavida
Journal: Blood (2009)
Regulatory Role of Host IL-17 Via Control of Host Macrophage Activation Contributes to Less Acute Gvhd
Authors: Rie Kuroda, Katsuaki Sato, Hideaki Maeba, Toshihiro Fujiki, Shintaro Mase, Raita Araki, Kazuhito Naka, Makoto Naito, Yoichiro Iwakura, Akihiro Yachie, Shoichi Koizumi, Ryosei Nishimura
Journal: Blood (2012)
NR4A3 Suppresses Lymphomagenesis In Vitro and In Vivo by Induction of Similar Patterns of Pro-Apoptotic Genes like NR4A1
Authors: Alexander JA Deutsch, Beate Rinner, Martin Pichler, Karoline Fechter, Hildegard T. Greinix, Chenguang Wang, Christine Beham-Schmid, Peter Neumeister
Journal: Blood (2016)
Role of Non-Driver Mutations and JAK2V617F Allele Burden in Myelofibrotic and Acute Myeloid Transformation of Patients with Polycythemia Vera and Essential Thrombocythemia
Authors: Alicia Senín, Conchi Fernández, Beatriz Bellosillo, Laura Camacho, Raquel Longaron, Anna Angona, Sara Montesdeoca, Carlos Besses, Alberto Alvarez-Larrán
Journal: Blood (2016)
A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma.
Authors: Shaji Kumar, Patrick J. Flynn, Wee Joo J Chng, Kenny Ieng Kit Lei, Jacob Allred, Kristina Laumann, Kevin Webster, Morie A Gertz, Angela Dispenzieri, Philip R. Greipp, Suzanne R. Hayman, Steven R. Zeldenrust, Charles Erlichman, S. Vincent Rajkumar, Martha Q. Lacy
Journal: Blood (2009)
Global Methylation Provides Independent Prognostic Information in Chronic Lymphocytic Leukemia and Is Associated with a Microrna Signature
Authors: Alfons Navarro, Gerardo Ferrer, Marina Díaz-Beyá, Carmen Muñoz, Rut Tejero, Tania Díaz, Mariano Monzó, Emili Montserrat
Journal: Blood (2012)
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial
Authors: Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai
Journal: Liver Cancer (2019)

In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial.Association between objective response and OS in patients treated with sorafenib (n = 103) or combination (n = 102) and all patients (n = 205) were analyzed. The median OS of responders was compared with that of non-responders. Landmark analyses were performed according to objective response at several fixed time points, as sensitivity analyses, and the effect on OS was evaluated by Cox regression analysis with objective response as a time-dependent covariate, with other prognostic factors.In the sorafenib group, OS of responders (n = 18) was significantly better than that of non-responders (n = 78) (p < 0.0001), where median OS was 27.2 (95% CI, 16.0-not reached) months for responders and 8.9 (95% CI, 6.5-12.6) months for non-responders. HRs from landmark analyses at 4, 6, and 8 months were 0.45 (p = 0.0330), 0.37 (p = 0.0053), and 0.36 (p = 0.0083), respectively. Objective response was an independent predictor of OS based on unstratified Cox regression analyses. In the all patients and the combination group, similar results were obtained.In the SILIUS trial, objective response by sorafenib assessed by mRECIST is an independent prognostic factor for OS in patients with HCC.
Successful Hematopoietic STEM CELL Mobilization with GRANULOCYTE Colony Stimulating FACTOR PLUS Plerixafor (MOZOBIL, AMD3100) IN POOR Mobilizers: A Single CENTER STUDY
Authors: Despina Mallouri, Ioanna Sakellari, Chrisa Apostolou, Panayotis Baliakas, Apostolia Papalexandri, Aliki Tsobanakou, Ioannis Batsis, Evangelia Yannaki, Christos Smias, Damianos Sotiropoulos, Athanasios Fassas, Achilles Anagnostopoulos
Journal: Blood (2010)
JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis
Authors: Jasper Smalberg, Edith Koehler, Sarwa Darwish Murad, Aurelie Plessier, Juan-Carlos Garcia-Pagan, Susana Seijó, Philippe Langlet, Jonel Trebicka, Massimo Primignani, Moniek De Maat, Dominique Valla, Harry Janssen, Frank Leebeek
Journal: Blood (2010)
In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations
Authors: Calogero Vetro, Torsten Haferlach, Manja Meggendorfer, Sabine Jeromin, Constance Regina Baer, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach
Journal: Blood (2016)
Novel Rearrangements and Mutations in the Alpha-Globin Gene Cluster Detected by a New Alpha-Globin Dosage Assay, Cation Exchange HPLC and Comprehensive DNA Sequencing.
Authors: Feras M. Hantash, Monica V. Gallivan, Mikula Mario, Starn Kelsey, Sheng-Biao Wang, Weimin Sun, Charles M. Strom
Journal: Blood (2006)
Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)
Authors: Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, Christian Recher, Romain Guieze, Emmanuel Raffoux, Krimo Bouabdallah, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, Andrea Toma, Herve Dombret, Norbert Vey, Simone Boehrer, Claude Gardin, Pierre Fenaux
Journal: Blood (2010)
Effects of Single Nucleotide Polymorphisms of the β2 Adrenergic Receptor and of Adenylate Cyclase on Sickle Red Cell Adhesion to Laminin.
Authors: Christine E. Eyler, Terry L. Jackson, Laura M. De Castro, Rahima Zennadi, Jeffery M. Vance, Allison Ashley-Koch, Marilyn J. Telen
Journal: Blood (2004)
Genetics of Teenage and Young Adult Acute Lymphoblastic T-Cell Leukaemia.
Authors: Frederik W Van Delft, Caroline L Furness, Marcela B Mansur, Lynne Minto, Julie Irving, Sameena Iqbal, Elda Noronha, Sue Colman, John G Gribben, Maria S Pombo-de-Oliveira, Mel Greaves
Journal: Blood (2012)
Molecular analysis of γ1, γ3, and α class switch recombination junctions in APOBEC3-deficient mice using high-throughput sequencing
Authors: Hussein Issaoui, Mélissa Ferrad, Nour Ghazzaui, Sandrine Lecardeur, Jeanne Cook-Moreau, François Boyer, Yves Denizot
Journal: Cellular and Molecular Immunology (2019)
All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid Receptor-Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell Lymphoma.
Authors: Amareshwar Singh, Andrew M Evens, Reilly Anderson, Jennifer Beckstead, Natesan Sankar, Savita Bhalla, Shuo Yang, Trudy Forte, Robert Ryan, Leo I. Gordon
Journal: Blood (2009)
Treatment Of Early Stage Follicular Lymphoma With Involved Field Radiotherapy and Rituximab. Role Of Bcl-2 Molecular Monitoring
Authors: Alessandro Pulsoni, Irene Della Starza, Pasqualina D'Urso, Gianna Maria D'Elia, Giorgia Annechini, Caterina Stefanizzi, Federico De Angelis, Sara Tricarico, Lavinia Grapulin, Marzia Cavalli, Robin FoÃ
Journal: Blood (2013)
Prognosis of Secondary Acute Myeloid Leukemia Is Affected by the Type of the Preceding Hematologic Disorders and the Presence of Trisomy 8.
Authors: Youngil Koh, Inho Kim, Hyun-Kyung Kim, Sung-Soo Yoon, Dong Soon Lee, Seonyang Park, Byoung Kook Kim
Journal: Blood (2009)
Scaffold with Micro/Macro‐Architecture for Myocardial Alignment Engineering into Complex 3D Cell Patterns
Authors: Wanqi Zhang, Zuyong Wang, Chao Xie, Xianwei Wang, Fangfang Luo, Minghui Hong, Rui Zhou, Chao Ma, Nan Lin, Jieyu Zhang, Xuefeng Hu, Jerry Kok Yen Chan, Feng Wen, Yunbing Wang
Journal: Advanced Healthcare Materials (2019)

Abstract Tissue structural anisotropy is an important basis for heart function. Attempts to regenerate the complicated heart‐tissue alignment has rarely featured macroscale 3D constructs required for myocardial tissue engineering. The feasibility of engineered scaffolds with micro/macro‐architecture for guiding spatial cell alignment following complex patterns is reported. The scaffold is composed of stackable dual‐structured layers with linear micro‐ridge/groove patterns and macro‐through‐hole arrays, which enable tailorable anisotropy and interconnective free space. When human mesenchymal stem cells are seeded on the scaffold, well‐organized spreading alignment showing the precise control in cellular orientation is significantly introduced over nonpatterned controls. Moreover, spatial cell distribution in the scaffold and directional changes of the layered linear patterns that made cell alignment orientations turning accordingly are observed, leading to the complex 3D pattern reconstruction of cellular alignment resembling natural myocardial tissue. This work validates the potential of micro/macro‐architecture engineering for spatial cell guidance. Scaffolds with this capability can be potentially used for biomanufacturing of the structural alignment in myocardial tissue engineering.
Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
Authors: Laurent Garderet, Emmanuelle Polge, mor Seny Gueye, Chaima Kellil, Jeanny Guelongo Okouango Ova, Eric Beohou, Myriam Labopin, Mohamad Mohty
Journal: Blood (2015)
Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study
Authors: Berengere Gruson, Olivier Lortholary, Danielle Canioni, marie-Olivia Chandesris, Fanny Lanternier, Bernard Grosbois, Cristina Livideanu, Thierry Lamy, Henri Sevestre, Claire Larroche, Aurélie Esparcieux, Guillaume Chaby, Jean Pierre Marolleau, Olivier Hermine, Gandhi Damaj
Journal: Blood (2011)
CD133+ Pluripotent Stem Cells for the Treatment of Chronic Liver Failure.
Authors: Lucia Catani, Stefania Lorenzini, Rosaria Giordano, Paolo Caraceni, Maria Rosa Motta, Valeria Giudice, Tiziana Montemurro, Ferdinando Giannone, Daria Sollazzo, Elisa Dan, Benedetta Nicolini, Francesca Chelli, Michele Baccarani, Mauro Bernardi, Francesco Losinno, Pietro Andreone, Roberto M. Lemoli
Journal: Blood (2010)
Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors
Authors: Teresa Ezponda, Relja Popovic, Yupeng Zheng, Behnam Nabet, Christine Will, Eliza C Small, Manuela Occhionorelli, Giovanni Tonon, Jonathan J. Keats, Neil L Kelleher, Jonathan D. Licht
Journal: Blood (2014)
Ex-Vivo Fucosylation Improves the Anti-Graft-Versus-Host-Disease Effects of Mesenchymal Stem Cells in the NOD/SCID/IL-2R Null Mouse Model
Authors: Jorge Galvez Silva, Mayela Mendt Vilchez, Imahashi Nobuhiko, Bruce R. Blazar, Patrick Zweidler-McKay, Katayoun Rezvani, Elizabeth J. Shpall
Journal: Blood (2016)
Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma
Authors: Karma Salem, Jihye Park, Claudia Freymond, Marzia Capelletti, Daisy Huynh, Antonio Sacco, Adriana Perilla Glen, Aaron M. Caola, Patrick Henrick, Eliezer Van Allen, David Liu, Aldo M. Roccaro, Nikhil C Munshi, Gad Getz, Irene M. Ghobrial, Salomon Manier
Journal: Blood (2016)
A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM)
Authors: Nathan C Nussbaum, Andrew Dougherty, Dan T. Vogl, Brendan M Weiss, David L Porter, E Paul Wileyto, Kathleen Cunningham, Patricia A. Mangan, Brenda K. Shelly, Heather DiFilippo, Edward A. Stadtmauer
Journal: Blood (2012)
Complete pathological response of colorectal liver metastases after neoadjuvant chemotherapy: myth or reality?
Authors: D. A. Wicherts, R. J. Haas de, F. Levi, T. Aloia, B. Paule, M. Bralet, F. Kunstlinger, D. Azoulay, D. Castaing, R. Adam
Journal: Journal of Clinical Oncology (2007)

4063 Background: A complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherapy has been shown unrelated to the real disappearance of active tumor. By contrast, a complete pathological response (PCR) could be more clinically relevant, but has not been explored. The aim of this study was to evaluate the incidence and outcome as well as predictive factors of PCR, in patients resected from CLM after neoadjuvant chemotherapy. Methods: In our institution 791 consecutive patients with CLM underwent liver resection after neoadjuvant chemotherapy. CCR was defined as the disappearance of all lesions after chemotherapy, and PCR was defined as the total necrosis of all metastases on the resection specimen. Both were selected from a prospective database. Patients with and without PCR were compared, survivals were determined and predictive factors for PCR were analyzed using a multivariate risk model. Results: There were 0.4% CCR (3/791) and 4% PCR (31/791). Among the 31 patients with PCR, the median number of CLM was 2.0 (range 1–13) with a maximum diameter = 3 cm for most cases (73%) at diagnosis. Ten patients (32%) had extrahepatic metastases. Compared to patients without PCR, patients with PCR were younger (p&lt; 0.05) and had a smaller maximum tumor size (p=0.007). Rate of objective response was higher (81% vs. 52%; p=0.002) and last chemotherapy regimen contained more frequently oxaliplatin than irinotecan (p=0.05). Number of chemotherapy cycles and treatment lines were not different. At multivariate analysis, 4 predictive factors of PCR were identified: age = 60 yrs, maximum size at diagnosis = 3 cm, CEA = 40 ng/ml at diagnosis and achievement of an objective response. The probability of PCR ranged from 0.2% when all were absent to 33.8% when all were present. PCR strongly impacted overall survival (OS) that was 69% and 62% at 5 and 10 years with a disease-free survival (DFS) of 42% for both. Conclusions: PCR concerns overall 4% of patients receiving neoadjuvant chemotherapy allowing for surgery, but as much as one third of those aged less than 60 years, developing response on liver metastases smaller than 3 cm, with low CEA values. Uncommon high survival rates are observed in this setting. PCR more than CCR is a reality and strongly impacts patient outcome. No significant financial relationships to disclose.
Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome
Authors: Anthea Peters, James A Russell, Andrew Daly, Nizar J Bahlis, Michelle Geddes, Peter Duggan, Mary Lynn Savoie, Douglas A. Stewart
Journal: Blood (2010)
Distinct Biomarker Profiles in Ex-Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection Vs CD3/19 Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation
Authors: Caroline R. Cantilena, Sawa Ito, Xin Tian, Prachi Jain, Fariba Chinian, Prathima Anandi, Upneet Chawla, Debbie Draper, Eleftheria Koklanaris, Jeanine Superata, David Stroncek, Pawel Muranski, John Barrett, Minoo Battiwalla
Journal: Blood (2016)
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients &gt;60 Years. Results from the SAL 60+ Trial
Authors: Christoph Röllig, Michael Kramer, Maria Gabrecht, Mathias Hänel, Regina Herbst, Ulrich Kaiser, Norbert Schmitz, Johannes Kullmer, Sebastian Fetscher, Hartmut Link, Luisa Mantovani-Löffler, Ulrich Krümpelmann, Thomas Neuhaus, Frank Heits, Hermann Einsele, Barbara Ritter, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, Brigitte Mohr, Markus Schaich, Uwe Platzbecker, Kerstin Schäfer-Eckart, Alwin Krämer, Wolfgang E Berdel, Hubert Serve, Gerhard Ehninger, Ulrich S. Schuler
Journal: Blood (2015)
Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.
Authors: Mirle Schemionek, Ulrich Steidl, Albrecht Schwab, Daniel G Tenen, Copland Mhairi, Tessa L. Holyoake, Christian Preisinger, Carsten Mueller-Tidow, Tim H Brümmendorf, Steffen Koschmieder
Journal: Blood (2012)
Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer
Authors: Akinori Sasaki, Akihito Kawazoe, Tetsuya Eto, Saori Mishima, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Kohei Shitara
Journal: Annals of Oncology (2019)
Targeting Neutrophil Aging and the Microbiota for the Treatment of Sickle Cell Disease
Authors: Dachuan Zhang, Grace Chen, Deepa Manwani, Arthur Mortha, Chunliang Xu, Jeremiah J. Faith, Robert D. Burk, Yuya Kunisaki, Jung-Eun Jang, Christoph Scheiermann, Miriam Merad, Paul S. Frenette
Journal: Blood (2015)
Aberrant Precursor B Lymphoid Blast Population in a Patient with Juvenile Myelomonocytic Leukemia
Authors: Saman Khalid Hashmi, Jyotinder Nain Punia, Amos S. Gaikwad, Kevin E. Fisher, Angshumoy Roy, Dolores H. Lopez-Terrada, Pulivarthi Rao, Jo Ringrose, Andrea N. Marcogliese, Rachel E Rau
Journal: Blood (2016)
Wireless Bioelectronics Towards Treatment of Glioblastoma Multiforme
Authors: Andie Shaw, Paola Sanjuan-Alberte, Richard Hague, Ruman Rahman, Frankie Rawson
Journal: Neuro-Oncology (2019)

Abstract ‘Bioelectronic therapies’ are defined as treatments that provide therapy via electrical stimulation. As electrochemical signalling is a key communication pathway of the human body, learning and modulating these signals could allow us to regenerate lost functions and restore health where previously regarded impossible. Bioelectronics do not yet fully exploit this possibility as they lack resolution and plasticity to fully merge with biology. We aim to negate these problems by pioneering the development of wireless bioelectronics. One exciting area we hope this can be applied is that of tumour treating fields (TTFs). TTFs apply electric fields to a tumour region, providing a non-invasive anti-mitotic treatment modality. This anti-mitotic behaviour arises due to dipole alignment and di-electrophoresis. However, an understanding of the exact mode of action has not yet been reached. We aim to improve this knowledge by analysing how healthy astrocytes vs glioblastoma cells behave in various electrical systems: comparing ionic currents with electric fields. Furthermore, we hope to improve targeting of TTFs through the in-situ growth of conductive structures, via wireless electrochemistry. Proof of concept has been achieved by wirelessly growing silver micro-wires in the presence of U251 glioblastoma cells. Wire growth has been optimised without the presence of cells, allowing controlled growth direction via electrode geometry. Wires range from 2–9µm in diameter and have been shown to be conductive through the completion of a circuit lighting an LED. Such structures could ultimately be grown in the region of a tumour, therefore therapeutically targeting the electric field to that site.
The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines.
Authors: Daniel Nowak, Norihiko Kawamata, Birte Niebuhr, Verena Nowak, Maximilian Mossner, Rahul R Nahar, Nils Heinrich Thoennissen, Gabriela B. Iwanski, Carol Stocking, Martin Dugas, Wolf Karsten Hofmann, Markus Müschen, Phillip H Koeffler
Journal: Blood (2009)
The Predictive Value of D-Dimers on the Occurrence of Thromboembolic Events and Death: A Prospective Multicentric Study.
Authors: Isabelle Mahe, Ludovic Drouet, Olivier Chassany, Claire Bal dit Sollier, Elizabeth Mazoyer, Sophie Minh-Muzeaux, Charles Caulin, Jean-François Bergmann
Journal: Blood (2005)
Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Authors: Herbert Eradat, Sebastian Grosicki, John Catalono, Walter Cosolo, Irina Dyagil, Thomas J Kipps, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, William Ho, Halyna Pylypenko
Journal: Blood (2012)
Efficacy and Safety of a Biosimilar Granulocyte-Colony Stimulating Factor for Stem Cell Mobilization before Autologous Hematopoietic Stem Cell Transplantation
Authors: Guillermo Martín-Sánchez, Cristina Amunarriz, Miriam Sanchez, Maria Aranzazu Bermudez, Lucrecia Yañez, Mercedes Colorado, Carlos Richard, Eulogio Conde, Jose Luis Arroyo
Journal: Blood (2016)